Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Emulate

Explore full profile

A privately held company that creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health

Boston, United StatesFounded 2014Biotech & Life Sciences
Valuation $250–500M Last recorded · 2024
Headcount <100 Current team size
Total funding $100–500M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Emulate and the history behind them.

About Emulate

Emulate Bio is a biotechnology startup that operates in the pharmaceutical and healthcare industry. The company specializes in the development and application of Organ-on-a-Chip technology, a cutting-edge tool that simulates human biology more accurately than traditional animal and spheroid models. This technology is designed to improve the success rate of clinical trials, enhance patient safety, and boost research and development productivity.

Emulate Bio's primary clients are researchers and pharmaceutical companies who are developing new drug therapies. The company provides them with a user-friendly platform that includes instruments, consumables, and software in a flexible, open format. This platform allows researchers to gain a deeper understanding of human biology, which in turn helps them to develop safer and more effective drugs.

The company's business model revolves around selling their Organ-on-a-Chip technology and related products to researchers and pharmaceutical companies. They also generate revenue by publishing research articles, such as their recent publication on integrating Liver-Chip data into drug safety assessments. This publication provides a framework that researchers can use to identify drug-induced liver injury risk, thereby improving the safety and efficiency of drug development workflows.

In summary, Emulate Bio is a promising startup that leverages advanced biotechnology to improve drug development processes, with the ultimate goal of enhancing human health and saving lives.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2014
Headquarters
Boston, United States
Employees
73
Open positions
5
Dealroom signal
68.1/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Testing, Biotechnology, Microfluidics, Spinout, Biotech and Pharma, medical testing, organ-on-chip, DT and LS, science-based
Business model
Manufacturing
Client focus
b2b

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES FOther financing Mar 2024 $47M $410M Qiming Venture Partners —
SERIES EOther financing Sep 2021 $82M $328M Perceptive Advisors · Northpond Ventures —
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Emulate website traffic

Latest recorded traffic for Emulate is 40K monthly website visits, down 11.1% over the last three months. Emulate's team declined 6.4% over the past year.

Latest monthly visits40K 3-month web change-11.1% 1-year team growth-6.4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

19 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • National Institutes of Health

Series A7 investors entered at this stage

  • +ND Capital
  • ATEL Ventures
  • Techammer
  • LabCorp
  • OS Fund
  • Hansjörg Wyss
  • ALS Finding a Cure

Series B and later9 investors entered at this stage

Other known investors2 additional known investors

  • Harvard University
  • Wyss Institute
Team profiled 28 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇺🇸 United States93%
🇬🇧 United Kingdom3.5%
🇨🇳 China1.8%
🇩🇪 Germany1.8%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Emulate on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Emulate’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.